ClinicalTrials.gg
CompletedNCT00642707Updated Jan 14, 2016Results posted

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

A Phase 2 interventional study of PRO 140 (humanized monoclonal antibody to CCR5) and Placebo Comparator in HIV -1 Infection and HIV Infections, sponsored by CytoDyn, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
1,333rd of 2,150
44 · median 60
Started
2008
with 112 others
Phase 2
478 of 2,802
7 open now
Registered
1,846th of 2,802
by date

Among the 2,802 studies in HIV Infections with a site in United States, this one is the 1,333rd largest by enrollment of the 2,150 interventional ones that give a count, is one of 113 that started in 2008, is one of 478 in phase 2, and was the 1,846th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,802 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is:

  1. To assess the antiviral activity of PRO 140
  2. To assess the safety and tolerability of PRO 140
  3. To generate additional PK, PD and safety data of PRO 140
03

Conditions studied

  • HIV -1 Infection
  • HIV Infections

Browse trials for

Keywords

  • HIV
  • Treatment Naïve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)
  2. Screening plasma -1 RNA ≥ 5,000 copies/mL
  3. CD4+ lymphocyte cell count ≥ 300 cells/mm3 and no documented count \< or = 250 cells/mm3
  4. Has not taken any antiretroviral therapy (ART) w/in 12 wks of Early Screening Visit
  5. Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit
  6. Clinically normal or "not (NCS)" resting
  7. Women of must have a negative serum pregnancy test at Late Screening Visit \& a negative urine pregnancy test w/in 72 hrs prior to first dose of study medication, \& be non-lactating. Male \& female subjects must agree not to participate in a conception process from Early Screening Visit through Day 59.

Exclusion criteria

Exclusion Criteria:

  1. CXCR4 tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ Assay.
  2. Females who are pregnant, lactating or breastfeeding, or who plan to become pregnant during the study.
  3. History of active hepatitis within the previous 24 wks
  4. Prior use of any entry, attachment, CCR5 co-receptor or fusion inhibitor, including PRO 140, experimental or approved.
  5. Any immunization or vaccination (including influenza vaccine) within 30 days prior to administration of study drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Arm 1

    PRO 140 for three single SC doses: Days 1, 8, and 15

    Drug: PRO 140 (humanized monoclonal antibody to CCR5)

  • Active comparator
    Arm 2

    PRO 140 for three single SC doses: Days 1, 8 and 15

    Drug: PRO 140 (humanized monoclonal antibody to CCR5)

  • Active comparator
    Arm 3

    PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8

    Drug: PRO 140 (humanized monoclonal antibody to CCR5)

  • Placebo comparator
    Arm 4

    PBO for three single SC doses: Days 1, 8 and 15

    Drug: Placebo Comparator

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Change in Viral Load Following Initiation of Treatment (Viral Load is Defined as HIV-1 Copies/mL and Expressed as log10 Copies/mL).

    The primary end point was the maximum change from baseline in viral load following initiation of treatment, defined as HIV-1 copies/mL, measured by the Roche Amplicor HIV-1 Monitor UltraSensitive™ Test (lower limit of detection \[LLD\] = 48 copies/mL).

    Time frame: 59 days

07

Results

Posted May 31, 2013

Participant flow

Recruitment started March 2008 and ended November 2008

Participant flow — Overall Study
MilestoneArm 1Arm 2Arm 3Arm 4
Started11111210
Completed1011128
Not completed1002
Withdrew: Adverse event0002
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryMaximum Change in Viral Load Following Initiation of Treatment (Viral Load is Defined as HIV-1 Copies/mL and Expressed as log10 Copies/mL).

The primary end point was the maximum change from baseline in viral load following initiation of treatment, defined as HIV-1 copies/mL, measured by the Roche Amplicor HIV-1 Monitor UltraSensitive™ Test (lower limit of detection \[LLD\] = 48 copies/mL).

Time frame:
59 days
Reported as:
Mean · Log10copies/HIV-1 RNA/mL
Maximum Change in Viral Load Following Initiation of Treatment (Viral Load is Defined as HIV-1 Copies/mL and Expressed as log10 Copies/mL).
Log10copies/HIV-1 RNA/mLArm 1Arm 2Arm 3Arm 4
Maximum Change in Viral Load Following Initiation of Treatment (Viral Load is Defined as HIV-1 Copies/mL and Expressed as log10 Copies/mL).-0.99 ± 0.558-1.65 ± 0.571-1.37 ± 0.891-0.23 ± 0.285

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1—0/11 (0%)9/11 (81.8%)
Arm 2—0/11 (0%)10/11 (90.9%)
Arm 3—3/12 (25%)11/12 (91.7%)
Arm 4—0/10 (0%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventArm 1Arm 2Arm 3Arm 4
Meningitis viralInfections and infestations0/110/111/10/10
Scrotal abscessInfections and infestations0/110/111/10/10
Anal cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)0/110/111/10/10
Most frequent other events
Showing 10 of 96
Most frequent other events
EventArm 1Arm 2Arm 3Arm 4
LymphadenopathyBlood and lymphatic system disorders3/111/111/120/10
DiarrhoeaGastrointestinal disorders1/113/112/120/10
HeadacheNervous system disorders3/110/112/121/10
Infusion site indurationGeneral disorders1/112/113/120/10
TachycardiaCardiac disorders1/110/110/122/10
Arthropod biteInjury, poisoning and procedural complications0/110/110/122/10
HypertensionVascular disorders0/111/111/122/10
FatigueGeneral disorders2/110/111/120/10
Injection site erythemaGeneral disorders2/110/110/120/10
Injection site indurationGeneral disorders2/111/110/120/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1Arm 2Arm 3Arm 4Total
<=18 years00000
Between 18 and 65 years1111121044
>=65 years00000
Age, Continuous
Age, Continuous(years)Arm 1Arm 2Arm 3Arm 4Total
Mean38.5 ± 5.1341.9 ± 5.4646.4 ± 8.1842.4 ± 7.4442.4 ± 7.09
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1Arm 2Arm 3Arm 4Total
Female11114
Male101011940
Region of Enrollment
Region of Enrollment(participants)Arm 1Arm 2Arm 3Arm 4Total
United States1111121044
08

Study locations

1 site
  • Progenics Pharmaceuticals, Inc.
    Tarrytown, New York 10591, United States
09

References and documents

Publications

  • Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190. PubMed 20377413 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2008
First posted
Mar 25, 2008
Start
Mar 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
May 31, 2013
Last update
Jan 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00642707
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Mar 25, 2008
Start date
Mar 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
May 31, 2013
Last update
Jan 14, 2016

Study contacts

Stephen Morris, MD, PhD
study director · Progenics Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion